Tumor News and Research

RSS

Loss of HOXA5 protein may allow breast cancer cells to thrive

Many breast cancers are marked by a lack of HOXA5 protein, a gene product known to control cell differentiation and death, and lower levels of the protein correspond to poorer outcomes for patients.

20 May 2016

Radiation-immunotherapy combination can help treat melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in a review article.

20 May 2016

Borrowed immune system may help combat cancer

A new step in cancer immunotherapy: researchers from the University of Oslo/Oslo University Hospital and the Netherlands Cancer Institute show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.

20 May 2016

Microglia plays vital role in reducing effects of cocaine in the brain

A type of brain cell known as microglia plays a key role in reducing the effects of cocaine in the brain, according to a major study by a team from the Research Institute of the McGill University Health Centre in Montreal.

20 May 2016

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.

19 May 2016

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Prostate cancer is the second leading cause of mortality among American men with the highest incidence rate of all cancers reported in the U.S. Male sex hormones testosterone (T) and 5α-dihydrotestosterone (5α-DHT) promote prostate cancer progression.

19 May 2016

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

INSIGHTEC congratulates the medical team at Imperial College Healthcare NHS Trust for performing the first MR-guided focused ultrasound treatment in the United Kingdom for prostate cancer.

19 May 2016

Flavopiridol drug could be effective strategy to impair brain cancer growth

Glioblastoma, the most common form of brain cancer is a deadly disease for which at present there is no cure. Now, researchers have published research results that show how repurposing the old drug flavopiridol could be an effective strategy to cut short sugar availability and impair cancer growth.

19 May 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

19 May 2016

Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

A new study shows that repeated radiation therapy used to target tumors in the brain may not be as safe to healthy brain cells as previously assumed.

19 May 2016

Play-based procedural preparation helps reduce sedation use and costs tied to cranial radiation therapy

New research from St. Jude Children's Research Hospital shows support interventions by child life specialists decrease sedation use and costs associated with cranial radiation therapy.

19 May 2016

Novel VIPA-based spectroscopy allows researchers to obtain entire Brillouin spectrum in a single shot

At a microscopic level, every material contains spontaneous sound waves -- acoustic phonons -- that have properties dependent on the material's mechanical properties.

18 May 2016

Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.

18 May 2016

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness.

18 May 2016

Research on immune system sets stage for novel approach to cancer immunotherapy

Basic research into the dual nature of certain immune system cells has set the stage for a new approach to cancer immunotherapy that avoids some of the shortcomings associated with other methods, scientists at Dana-Farber Cancer Institute report in a new study in the Proceedings of the National Academy of Sciences.

17 May 2016

Risk factors for hospital readmission after pediatric neurosurgical procedures

Researchers at The University of Alabama at Birmingham have determined specific risk factors associated with hospital readmission following pediatric neurosurgery.

17 May 2016

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

Researchers reveal new mechanism that helps breast cancer cells engage MDSCs

Not every breast cancer tumor follows the same path to grow. Some tumors have the assistance of myeloid-derived suppressor cells (MDSCs), a diverse type of immune cell involved in the suppression of the body's response against tumors.

17 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

Genomic cfDNA profiling feasible in metastatic CRPC

Comprehensive genomic profiling of cell-free DNA can provide clinically useful information in men with castration-resistant prostate cancer treated with enzalutamide, research indicates.

14 May 2016

Tumor News and Research

Loss of HOXA5 protein may allow breast cancer cells to thrive

Radiation-immunotherapy combination can help treat melanoma

Borrowed immune system may help combat cancer

Microglia plays vital role in reducing effects of cocaine in the brain

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

Flavopiridol drug could be effective strategy to impair brain cancer growth

Tecentriq drug gets FDA approval to treat urothelial carcinoma

Conventional repeated radiation treatments may offer no major benefit to brain tumor patients

Play-based procedural preparation helps reduce sedation use and costs tied to cranial radiation therapy

Novel VIPA-based spectroscopy allows researchers to obtain entire Brillouin spectrum in a single shot

Targeting ERK and compensatory pathways with drug inhibitors halts colorectal cancer growth

Biovica acquires cSens AB - creating opportunities for solving cancer diagnostic challenges

Research on immune system sets stage for novel approach to cancer immunotherapy

Risk factors for hospital readmission after pediatric neurosurgical procedures

Novel therapeutic approach to treat leukaemia patients

Researchers reveal new mechanism that helps breast cancer cells engage MDSCs

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Genomic cfDNA profiling feasible in metastatic CRPC

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News